A review on diabetic neuropathy and development of sustained release tablet containing ‘Epalrestat’

Abstract

Pain is a common sensation which associates distressing feeling, often caused by intense or damaging stimuli.. But if pain gets into nerves with a tingling, shooting sensation or like an electrical flow of current in nerve pathways then it becomes an exceptional term which is more difficult to explain or tolerate and known as ‘Diabetic Neuropathy’ (DN) complication caused by long term Diabetic condition. In accordance to the patient comorbidities and pain phenotype treatment for DN should be advised. In the context of treatment, a new addition here is Epalrestat drug whose (Epalrestat 50mg) efficacy and safety have been established by clinical trials, however compliance still remains to be a challenge. This review holds a detailed glimpse of DN and stands to design and assess a sustained release dosage form of Epalrestat in order to attain prolonged therapeutic effect with minimum side effects against this neuropathic complication.